Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Hanauer

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
Gastroenterology|October 26, 2001
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trialW J Sandborn, S B Hanauer, S Katz, et al.
Inflammatory Bowel Diseases|March 4, 2000
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998C Gasche, J Scholmerich, J Brynskov, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2018
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study)A B Friedman, S J Brown, P Bampton, et al.
Human Molecular Genetics|May 18, 2000
Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel diseaseJ H Cho, D L Nicolae, R Ramos, et al.
Gut|February 15, 2007
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialW J Sandborn, S B Hanauer, P Rutgeerts, et al.
Gastroenterology|December 13, 2000
Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severityS R Brant, C I Panhuysen, J E Bailey-Wilson, et al.
The New England Journal of Medicine|June 1, 2000
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group InvestigatorsB G Feagan, R N Fedorak, E J Irvine, et al.
Gastroenterology|September 29, 1999
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseP Rutgeerts, G D'Haens, S Targan, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2018
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapyW J Sandborn, P Rutgeerts, C Gasink, et al.
Gastroenterology|March 1, 1997
Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591W G Roberts, T J Simon, R G Berlin, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Gastroenterology|October 26, 2001
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trialW J Sandborn, S B Hanauer, S Katz, et al.
Inflammatory Bowel Diseases|March 4, 2000
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998C Gasche, J Scholmerich, J Brynskov, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2018
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study)A B Friedman, S J Brown, P Bampton, et al.
Human Molecular Genetics|May 18, 2000
Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel diseaseJ H Cho, D L Nicolae, R Ramos, et al.
Gut|February 15, 2007
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialW J Sandborn, S B Hanauer, P Rutgeerts, et al.
Gastroenterology|December 13, 2000
Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severityS R Brant, C I Panhuysen, J E Bailey-Wilson, et al.
The New England Journal of Medicine|June 1, 2000
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group InvestigatorsB G Feagan, R N Fedorak, E J Irvine, et al.
Gastroenterology|September 29, 1999
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseP Rutgeerts, G D'Haens, S Targan, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2018
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapyW J Sandborn, P Rutgeerts, C Gasink, et al.
Gastroenterology|March 1, 1997
Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591W G Roberts, T J Simon, R G Berlin, et al.
Pageof 15